Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer

Inclusion Criteria: * Histologically or cytologically confirmed epithelial ovarian cancer, primary peritoneal serous cancer, papillary serous endometrial cancer, or fallopian tube cancer * Must have responded and remained clinically stable (as defined by normal clinical examination, normal serum CA125 level and normal CT scan) after first-line platinum-based regimen followed by bevacizumab maintenance therapy * Must have developed relapsed disease at least 3 months after completion of bevacizumab maintenance therapy as defined by a) development of new, measurable lesions by RECIST criteria, but no lesion with maximum diameter greater than 3 centimeters OR b) newly elevated CA125 level at least 2 x ULN on 2 separate occasions, obtained at least 1 day but not more than 3 months apart * ECOG Performance Status 0-2 * No prior cytotoxic chemotherapy or biologic therapy for disease recurrence allowed * Prior hormonal-based therapy for ovarian, primary peritoneal serous or fallopian tube cancer is allowed * Toxic side effects related to prior chemotherapy or hormonal therapy must have resolved to grade one or less or to baseline before initiation of bevacizumab * 18 years of age or older * Life expectancy of 6 months or greater * Normal organ and marrow function as outlined in the protocol Exclusion Criteria: * Prior cytotoxic chemotherapy or biologic therapy for disease recurrence * Known CNS disease, except for treated brain metastasis * Pregnancy or breast feeding * Uncontrolled intercurrent illness including, but not limited to hypertension, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 0, or anticipation of need for major surgical procedure during the course of the study * Core biopsy or other minor surgical procedure, excluding placement of a vascular device, within 7 days prior to enrollment * History of abdominal fistula, GI perforation, intra-abdominal abscess, or CT evidence of bowel obstruction or bowel wall thickening * Symptoms of intestinal obstruction, or requirement of parenteral hydration and/or nutrition * History of active malignancy during the last 3 years, except non-melanomatous skin cancer or in situ breast or cervical cancer * Evidence of preexisting uncontrolled hypertension. If patient has hypertension, it must be medically controlled (\< 150/90) prior to starting bevacizumab * Proteinuria at screening * Dementia or significantly altered mental status that would prohibit the understanding and/or giving of informed consent * Therapeutic anticoagulation is not by itself and exclusion criterion. However, for certain high risk patients on therapeutic anticoagulation, eligibility will be determined after discussion with the overall PI * Any active bleeding * Serious, non-healing wound, ulcer, or bone fracture * Prior history of hypertensive crisis or hypertensive encephalopathy * NYHA Grade II or greater congestive heart failure * History of myocardial infarction or unstable angina within 6 months prior to Day 1 * History of stroke or transient ischemic attack within 6 months prior to day 1 * Significant vascular disease within 6 months prior to day 1 * History of hemoptysis within 1 month prior to day 1 * Presence of measurable lesion(s) by RECIST criteria with maximum diameter greater than 3 centimeters